All products have special prices for bulk purchase, please contact for more details if required.

Cat. No.: ECLT-0.2 (for 10mM×0.2ml)

Cat. No.: ECLT-25 (for 25mg)

Cat. No.: ECLT-100 (for 100mg)

Description

Esculetin, primarily extracted from the bark of Fraxinus rhynchophylla, serves as an active ingredient. It inhibits platelet-derived growth factor (PDGF)-induced phenotype switching in airway smooth muscle cells (ASMCs) by targeting the PI3K/Akt pathway. Additionally, esculetin exhibits antioxidant, anti-inflammatory, and antitumor properties.

Basic Information

• Aliases: 6,7-Dihydroxycoumarin; Aesculetin; Cichorigenin; Esculetol
• Source: Fraxinus chinensis Roxb; Euphorbia lathyris L．
• Compound type: Phenylpropanoids＞Coumarins
• Chemical Formula: C₉H₆O₄
• Molecular Weight: 178.14
• CAS Number: 305-01-1
• Purity: 98%, HPLC
• Solvent/Solubility: DMSO: 33 mg/ml (185.2 mM); Ethanol: <1 mg/ml; Water: <1 mg/ml
• Solution Preparation: 2mg can be dissolved in 1.12ml of DMSO, or alternatively, 1.78mg can be dissolved in 1ml of DMSO to prepare a 10mM solution.

Signaling Pathway

In Vitro Study

Esculetin induces G1 phase cell cycle arrest, reducing cell proliferation by down-regulating cyclin D1/CDK4 and cyclin E/CDK2 complexes through p27KIP activation. Its anti-proliferative effect on HCC cells is concentration- and time-dependent, with an IC50 value of 2.24 mM. It induces apoptosis in SMMC-7721 cells by blocking the cell cycle at S phase and increasing caspase-3 and caspase-9 activity, while not affecting caspase-8 activity. Esculetin treatment leads to mitochondrial membrane potential collapse both in vitro and in vivo, along with upregulated Bax expression and downregulated Bcl-2 expression at transcriptional and translational levels. It demonstrates antiproliferative activity against hepatocellular carcinoma through initiation of a mitochondrial-mediated, caspase-dependent apoptosis pathway.

In Vivo Study

Esculetin demonstrates a significant reduction in tumor growth in mice inoculated with Hepa1-6 cells. As the dosage of esculetin increases, tumor weight decreases by 20.33%, 40.37%, and 55.42%. Importantly, no discernible toxicity is observed in this animal study. Additionally, in a rat model of inflammatory bowel disease induced by trinitrobenzenesulfonic acid, esculetin administered at a dose of 5 mg/kg exhibits anti-inflammatory activity in the intestines.

Clinical Trial

N/A

Storage

Store at -20°C for at least one year. The solid powder is stable at 4°C for at least one month. If dissolved in a non-DMSO solvent, it is recommended to aliquot and store at -80°C for up to six months.

Precautions

• This product may have a certain degree of toxicity to the human body. Please take appropriate precautions to avoid direct contact with the body or inhalation.
• This product is for scientific research use only by professionals and is not intended for clinical diagnosis or treatment, food, or pharmaceutical purposes. It should not be stored in ordinary residential areas.
• For your safety and health, please wear laboratory attire and disposable gloves while handling.

Only for research and not intended for treatment of humans or animals

Journals Using SBS Genetech Products                                       Universities Using SBS Genetech Products

SBS Genetech is a long-term sponsor of Cold Spring Harbor Laboratory